Unlike most proteins, which are localized within a single subcellular compartment in the eucaryotic cell, the simian virus 40 (SV40) large tumor antigen (T-ag) is associated with both the nucleus and the plasma membrane. Current knowledge of protein processing would predict a role for the secretory pathway in the biosynthesis and transport of at least a subpopulation of T-ag to account for certain of its chemical modifications and for its ability to reach the cell surface. We have examined this prediction by using in vitro translation and translocation experiments. Preliminary experiments established that translation of T-ag was detectable with as little as 0.1 ,ug of the total cytoplasmic RNA from SV40-infected cells. Therefore, by using a 100-fold excess of this RNA, the sensitivity of the assays was above the limits necessary to detect the theoretical fraction of RNA equivalent to the subpopulation of plasma-membrane-associated T-ag (2 to 5% of total T-ag). In contrast to a control rotavirus glycoprotein, the electrophoretic mobility of T-ag was not changed by the addition of microsomal vesicles to the in vitro translation mixture. Furthermore, T-ag did not undergo translocation in the presence of microsomal vesicles, as evidenced by its sensitivity to trypsin treatment and its absence in the purified vesicles. Identical results were obtained with either cytoplasmic RNA from SV40-infected cells or SV40 early RNA transcribed in vitro from a recombinant plasmid containing the SP6 promoter. SV40 early mRNA in infected cells was detected in association with free, but not with membranebound, polyribosomes. Finally, monensin, an inhibitor of Golgi function, failed to specifically prevent either glycosylation or cell surface expression of T-ag, although it did depress overall protein synthesis in TC-7 cells. We conclude from these observations that the constituent organelles of the secretory pathway are not involved in the biosynthesis, modification, or intracellular transport of T-ag. The initial step in the pathway of T-ag biosynthesis appears to be translation on free cytoplasmic polyribosomes. With the exclusion of the secretory pathway, we suggest that T-ag glycosylation, palmitylation, and transport to the plasma membrane are accomplished by previously unrecognized cellular mechanisms.
Unlike most proteins, which are localized within a single subcellular compartment in the eucaryotic cell, the simian virus 40 (SV40) large tumor antigen (T-ag) is associated with both the nucleus and the plasma membrane. Current knowledge of protein processing would predict a role for the secretory pathway in the biosynthesis and transport of at least a subpopulation of T-ag to account for certain of its chemical modifications and for its ability to reach the cell surface. We have examined this prediction by using in vitro translation and translocation experiments. Preliminary experiments established that translation of T-ag was detectable with as little as 0.1 ,ug of the total cytoplasmic RNA from SV40-infected cells. Therefore, by using a 100-fold excess of this RNA, the sensitivity of the assays was above the limits necessary to detect the theoretical fraction of RNA equivalent to the subpopulation of plasma-membrane-associated T-ag (2 to 5% of total T-ag). In contrast to a control rotavirus glycoprotein, the electrophoretic mobility of T-ag was not changed by the addition of microsomal vesicles to the in vitro translation mixture. Furthermore, T-ag did not undergo translocation in the presence of microsomal vesicles, as evidenced by its sensitivity to trypsin treatment and its absence in the purified vesicles. Identical results were obtained with either cytoplasmic RNA from SV40-infected cells or SV40 early RNA transcribed in vitro from a recombinant plasmid containing the SP6 promoter. SV40 early mRNA in infected cells was detected in association with free, but not with membranebound, polyribosomes. Finally, monensin, an inhibitor of Golgi function, failed to specifically prevent either glycosylation or cell surface expression of T-ag, although it did depress overall protein synthesis in TC-7 cells. We conclude from these observations that the constituent organelles of the secretory pathway are not involved in the biosynthesis, modification, or intracellular transport of T-ag. The initial step in the pathway of T-ag biosynthesis appears to be translation on free cytoplasmic polyribosomes. With the exclusion of the secretory pathway, we suggest that T-ag glycosylation, palmitylation, and transport to the plasma membrane are accomplished by previously unrecognized cellular mechanisms.
Simian virus 40 (SV40) is a small, nonenveloped virus that productively infects some cell types and can transform others (reviewed in reference 80). The double-stranded DNA genome of SV40 encodes a polypeptide, large tumor antigen (T-ag), that provides many different functions required for viral infection or transformation (reviewed in references 6 and 61). One possible molecular basis for the multifunctional capacity of T-ag is suggested by its unusual dual subcellular distribution (reviewed in references 6 and 61). Most (.95%) of the intracellular T-ag is localized within the nucleus (nT-ag), whereas the remainder is found at the cell surface in association with the plasma membrane (pmT-ag).
Recent studies have shown that T-ag contains a signal that is required for its nuclear localization and can induce the nuclear localization of heterologous, non-nuclear proteins (33, 34, 44, 45) . The identification of this signal represents a key step toward the elucidation of the mechanism by which T-ag is transported to the cell nucleus. In contrast, we know virtually nothing of the mechanism by which a minor subpopulation of T-ag escapes nuclear localization and, instead, becomes localized at the plasma membrane.
Typically, the biosynthesis and transport of plasmamembrane-bound proteins are accomplished by the secretory pathway (reviewed in references 63, 84, and 86) . This pathway involves the cotranslational insertion of nascent protein into the membrane of the rough endoplasmic reticulum (RER), a process that is partially mediated by a characteristic stretch of amino acids known as the signal sequence. The newly synthesized protein moves from the RER to the Golgi apparatus and, ultimately, to the plasma membrane. Various co-and posttranslational modifications, such as N-glycosylation, 0-glycosylation, and fatty acid acylation, including both myristylation and palmitylation, occur en route (reviewed in references 23, 37, 40, and 69). Some properties of T-ag suggest that the secretory pathway might be involved in its biosynthesis and transport, whereas others suggest that it is not involved.
It appears that at least a subpopulation of pmT-ag spans the plasma membrane. Immunological studies have shown that epitopes on opposite ends of the T-ag molecule are exposed on the surfaces of intact cells (2, 12, 21, 22, 64, 85) , and solubility studies suggest that radioiodinatable surface T-ag is associated with the plasma membrane lamina (39) . In addition, T-ag undergoes glycosylation (27, 70, 72) , and a subpopulation of pmT-ag undergoes palmitylation (38) . At first, these properties would seem to be consistent with a model in which T-ag would enter the secretory pathway by insertion into the membrane of the RER and would be glycosylated or palmitylated or both as it travels through the RER and Golgi apparatus. However, this model is difficult to reconcile with other known features of T-ag. First, the vast majority of the intracellular T-ag is quickly transported to the nucleus (44, 67, 71) . Although it is possible that a structural difference provides a sorting signal that specifically redirects the pmT-ag subpopulation into the secretory pathway, recent comparisons of nT-ag and pmT-ag revealed no such differences (28) . Second, the amino acid sequence of T-ag lacks a typical signal sequence (reviewed in reference 6), precluding the most well-documented means of entering the secretory pathway. Third, although T-ag contains a consensus N-glycosylation site (26) , it does not undergo N-glycosylation (27, 72) , suggesting that it is not exposed to oligosaccharyl transferase in the lumen of the RER (40) . That this site is available for glycosylation was shown by a study in which T-ag was forced into the secretory pathway by virtue of a heterologous signal sequence; a chimeric T-ag molecule, equipped with the amino-terminal signal sequence of the influenza hemagglutinin (HA), underwent Nglycosylation (73) . Interestingly, the chimeric protein did not undergo normal movement to the cell surface, providing further indirect evidence that the secretory pathway is not normally involved in the biosynthesis and transport of wildtype (WT) T-ag (73) .
In this study, we have used a variety of in vitro and in vivo approaches to examine directly the role of the secretory pathway in the biosynthesis and processing of SV40 T-ag. The results show that the secretory pathway is not involved. This finding suggests that previously unrecognized mechanisms exist for the glycosylation, acylation, and intracellular transport of T-ag and probably of other eucaryotic proteins as well.
MATERIALS AND METHODS
Cells and viruses. TC-7 cells, a clonal derivative of the CV-1 line (62), were grown in an enriched minimal essential medium (GIBCO Laboratories, Grand Island, N.Y.) as previously described (54) . MA104 cells were grown in medium 199 (GIBCO) supplemented with 5% fetal bovine serum, 0.03% glutamine, 0.075% sodium bicarbonate, 100 U of penicillin per ml, and 100 ,ug of streptomycin per ml (17) .
The Baylor strain of WT SV40 (77) was passaged at low multiplicity of infection and plaque assayed in TC-7 cells (55) . The Indiana strain of WT vesicular stomatitis virus (VSV) was passaged and assayed in TC-7 cells as described for SV40, except that the infected cells were not freezethawed. Clone 3 of the simian rotavirus SAil (16) was passaged at low multiplicity of infection and plaque assayed in MA104 cells (17) .
Antisera. Normal hamster serum was purchased from PelFreeze Biologicals (Rogers, Ark.). Hamster ascitic fluid (HAF), a polyclonal antiserum with strong reactivity against SV40 T-ag, was prepared as previously described (42) . Monospecific guinea pig antiserum against the gel-purified outer capsid glycoprotein of SAil (aVP7) has been described previously (13) . Rabbit Preparation of SAll RNA. Rotavirus mRNA was synthesized in vitro by using the RNA polymerase activity endogenous to purified virus. The mRNA was isolated from the min at 27,000 x g, and stored in small samples at -70°C. Prior to use, the lysate was supplemented with 8 ,M bovine hemin (Sigma; type I), 10 mM creatine phosphokinase (Sigma; type I), 25 FM amino acids except methionine, 90 mM KCl, 0.5 mM MgCl2, and 1 mM CaCl2 and then was treated with micrococcal nuclease (Sigma). The nuclease was inactivated with ethylene glycol-bis-(P-aminoethyl ether)-N,N'-tetraacetic acid, and the treated lysate was further supplemented with 60 ,ug of wheat germ tRNA (Sigma) per ml. The treated and reconstituted lysate was used immediately or was stored at -70°C for 3 to 4 months.
For cell-free translation, 90 U of RNasin (PromegaBiotec), 25 ,uCi of [35S]methionine (1,000 to 1,500 Ci/mmol; Amersham Corp., Arlington Heights, Ill.), and various amounts of RNA were added to 90 ,ul of the lysate, and the mixture was incubated for 1 h at 30°C. The reaction was terminated by RNase treatment, and the samples were diluted to 1 ml with cold extraction buffer (50 mM Tris hydrochloride [pH 8.0], 100 mM NaCl, 1% [vol/vol] Nonidet P-40) containing 200 ,uM leupeptin (Sigma) (29) . The solubilized samples were then clarified and immunoprecipitated as described below.
In some experiments, cell-free translation of RNA was carried out in the presence of canine pancreatic microsomal vesicles (4). The microsomes were prepared by the method of Shields and Blobel (74) as previously described (14) and were stored in 50% glycerol at -70°C. Translations were performed as described above, but with the addition of 3 to 6 A280 units of the microsome preparation and 3 mM tetracaine hydrochloride. Samples were immunoprecipitated either immediately after translation or after a 1-h treatment with 100 ,ug of tolylsulfonyl phenylalanyl chloromethyl ketone-trypsin (Worthington Enzymes, Freehold, N.J.) per ml (87). Trypsin digests were performed at 22°C in the presence or absence of 1% (vol/vol) Triton X-100 (Sigma). Alternatively, the reaction mixture was separated into soluble and particulate (microsomal) fractions prior to immunoprecipitation (32 (27) . The precise labeling conditions used in individual experiments and the details of inhibitor treatments are noted in the figure legends. After being labeled, the monolayers were washed and extracted with extraction buffer supplemented with leupeptin, and the extracts were clarified. The extracts were then treated with antiserum and fixed Staphylococcus aureus Cowan I (36) , and the resulting immunoprecipitates were washed and disrupted as previously described (27) . The disrupted immunoprecipitates were analyzed by SDS-polyacrylamide gel electrophoresis as previously described (75), and the gels were impregnated with Autofluor (National Diagnostics, Somerville, N.J.), dried, and exposed to Kodak XAR-5 film at -70°C. In some experiments, bands of interest were excised from dried gels and solubilized by the method of Mahin and Lofberg (48) , and radioactivity was quantitated by liquid scintillation spectroscopy with a Beckman model LS-250 spectrometer.
Cell surface labeling. Surface proteins of intact cells were labeled by the lactoperoxidase-catalyzed radioiodination method as previously described (49, 76) . 
RESULTS
Cell-free synthesis of SV40 T-ag. Preliminary experiments were performed to establish the specificity and sensitivity of the cell-free translation reaction for SV40 T-ag (Fig. 1) . In the absence of exogenous RNA, no newly synthesized proteins were immunoprecipitated from the reaction mixture, indicating that the level of endogenous protein synthesis was low (panel A, lanes 3 and 4). The addition of cytoplasmic RNA from SV40-infected cells resulted in the synthesis of several proteins, most of which were nonspecifically immunoprecipitated with both normal hamster serum and HAF (panel A, lanes 5 and 6). However, T-ag was the predominant protein product, and it was specifically immunoprecipitated with HAF (panel A, lane 6). As previously reported by Prives et al. (59) and Paucha et al. (58) , the electrophoretic mobility of T-ag synthesized in the cell-free system (panel A, lane 6) was identical to that of T-ag synthesized in SV40-infected cells (panel A, lanes 2 and 7); both migrated with an apparent molecular weight of about 90,000. (Although the in vitro product appears to migrate slightly behind the in vivo product in Fig. 1A , this difference was not reproducible and probably resulted from distortion of this particular gel when it was dried.) This result is consistent with the notion that chemical modifications of T-ag that occur in vivo but not in vitro have no detectable influence on its electrophoretic mobility. As previously suggested by Denhardt and Crawford (11) , the primary amino acid sequence near the carboxy terminus of T-ag induces an anomaly in its electrophoretic behavior that appears to override and obscure any effects of modifications.
The rabbit reticulocyte system provided excellent sensitivity, since T-ag was detectably translated from as little as 0.1 ,ug of the cytoplasmic RNA preparation (Fig. IB, lane 3) . On the basis of this result and previous estimates that the pmT-ag subpopulation comprises about 2 to 5% of the total T-ag (43, 76), we used 10 ,ug (a 100-fold excess) of RNA for all subsequent cell-free translation experiments. This ensured the detectable translation of a fraction of the input RNA equivalent to the pmT-ag subpopulation. We considered this to be important in case pmT-ag is translated from a subpopulation of SV40 early mRNA that interacts with the early components of the cellular secretory pathway. (In fact, a faint T-ag band was detectable in the original autoradiogram when only 0.01 pug of RNA was used, indicating that the sensitivity of the assay was well within the theoretical required limits.) It must be emphasized, however, that this is strictly a hypothetical possibility; there is no evidence for more than one T-ag-encoding mRNA population.
In vitro translocation of T-ag. The ability of T-ag or the pmT-ag subpopulation to enter the secretory pathway was examined by using two different in vitro translocation assays. The first was a protease protection assay (87) involving the cell-free translation of RNA in the presence of microsomal vesicles, followed by treatment of the reaction mixture with trypsin and analysis by immunoprecipitation and SDS-polyacrylamide gel electrophoresis. With this assay, the protein of interest will be detected only if translocation occurs, because it must enter the microsomal vesicle to be protected from the action of the exogenous protease. The second was a copurification assay (32) , in which RNA is translated in the presence of microsomal vesicles, the reaction mixture is separated into soluble and particulate fractions by centrifugation, and each fraction is assayed by immunoprecipitation and SDS-polyacrylamide gel electrophoresis. In this case, the ability of a protein to copurify with the microsomes in the particulate fraction indicates that it has undergone translocation. A viral glycoprotein known to enter the secretory pathway at the level of the RER, VP7 of rotavirus SAl (reviewed in reference 15), served as a positive control in both assays. Although the rotavirus VP7 is a more heavily glycosylated protein than T-ag, it utilizes a typical mechanism to enter the secretory pathway, and it represented a good indicator that the various assays were behaving properly.
The results of the positive control for the protease protection assay are shown in Fig. 2A The results of analogous experiments were quite different for SV40 T-ag (Fig. 2B) . First, there was no detectable difference in the apparent molecular weight of T-ag synthesized in the absence (lane 1) or presence (lane 2) of microsomal vesicles. Second, T-ag did not cross the membrane of the microsomal vesicles, as evidenced by its complete susceptibility to trypsin digestion in the absence of detergent (lane 3). A 1-month overexposure, which was sufficient to detect T-ag synthesized from only 1% of the RNA used in this experiment (Fig. 1B, lane 3) , still revealed no trace of a T-ag band in lane 3 (data not shown). These results suggest that T-ag does not enter the cellular secretory pathway, at least not by translocation across the membrane of the RER.
It was possible, however, that T-ag was translocated, but that only a minimal domain of the molecule crossed the membrane of the microsomal vesicle. If so, most of the molecule would still be accessible for trypsin digestion and an intact T-ag band would not be observed. To address this possibility, we used another approach, the copurification assay, to determine whether T-ag underwent translocation (Fig. 3) . Initially, the translation mixture was simply microfuged for 1 h, and the supernatant and pellet fractions were immunoprecipitated for T-ag. T-ag was not detected in association with the microsomal vesicles in the pellet (lane 3) but was quantitatively recovered from the supernatant fluid (lane 2; compare with the unfractionated mixture in lane 1). In a similar but more rigorous experiment, the cell-free translation mixture was ultracentrifuged through a high-saltsucrose cushion to pellet the microsomes. T-ag failed to copurify with the microsomal vesicles (lane 5); it was recovered from the supernatant fraction (lane 4). In contrast, the mature VP7 glycoprotein copurified with the microsomal . . " ' In the preceding experiments, unselected cytoplasmic RNA was used for the cell-free translation of T-ag. Because SV40 early mRNA represents only about 0.1% of the total cytoplasmic RNA in SV40-infected cells (59) , it was possible that T-ag failed to undergo translocation because this minor mRNA population was outcompeted for the cellular machinery required to cross the RER membrane. For example, unrelated cellular mRNA species might have effectively occupied all of the signal recognition particle (83) in the lysate or the signal recognition particle receptor sites (18) in the microsomal membranes. To circumvent this possible complication, we constructed a recombinant plasmid (pSPT) in which a cDNA copy of T-ag mRNA was positioned behind an SP6 promoter. This plasmid was used to synthesize essentially pure SV40 early RNA in vitro, which was used, in turn, for in vitro translocation experiments analogous to those described above. Identical results were obtained with these pure mRNA preparations. Translocation of T-ag across the membrane of microsomal vesicles was not detected by either protease protection or copurification assays (Fig. 4) . 10) were immunoprecipitated. All immunoprecipitates were washed, disrupted, and analyzed on an 8% acrylamide gel. This photograph is of an autoradiogram exposed for 1 day. Molecular weight markers are given in thousands.
suggest that T-ag does not enter the secretory pathway in vivo, at least not at the level of the RER.
In vivo localization of T-ag biosynthesis. If T-ag is synthesized and transported to the cell surface through the secretory pathway, current models of this pathway would predict that at least a subpopulation of the SV40 early mRNA would be translated by membrane-bound polyribosomes. This prediction presented an in vivo approach by which to assess the role of the secretory pathway in T-ag biosynthesis and transport, i.e., free and membrane-bound polyribosomes were purified from SV40-infected cells and examined separately for the presence of SV40 early mRNA by cell-free translation (Fig. 5) . RNA extracted from the purified membrane-bound polyribosomes did not result in the translation of detectable T-ag (lane 2), whereas RNA extracted from free polyribosomes purified from the same cells did result in such translation (lane 3). In both cases, 10 ,ug of RNA was added to the cell-free translation system, but it can be noted that less T-ag was synthesized than with total cell RNA (lane 1). The amount of translatable mRNA in the polysomal RNA preparations was probably less than in the unfractionated RNA preparation, presumably because of RNA degradation during cellular fractionation procedures. The important comparison in this experiment was between the two polysome fractions, rather than between fractionated and unfractionated RNA, and we assumed that such degradation would be comparable in the two fractions. Fortunately, since this separation enriched for RNA in the membrane-bound fraction that would give translocatable products, the sensitivity of the assay was effectively enhanced. All the T-ag RNA that J. VIROL.
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on July 8, 2017 by guest http://jvi.asm.org/ Downloaded from might have been present in the bound fraction should have generated translocatable T-ag, but none was detected. This result suggests that the T-ag in SV40-infected cells is translated by free, and not by membrane-bound, polyribosomes. The failure to detect any viral mRNA in the membranebound polyribosome fraction is inconsistent with a role for the secretory pathway in the biosynthesis and transport of this protein to the cell surface. It should be noted that this approach has been commonly used to determine the sites of synthesis of other viral proteins (for examples, see references 7, 53, and 60).
Role of the Golgi apparatus in T-ag biosynthesis and transport. Although the results described above suggested that T-ag does not enter the secretory pathway by translocation across the membrane of the RER, we considered the possibility that it might somehow circumvent this early event and enter the pathway at the level of the Golgi apparatus. Such a mechanism might explain the ability of a subpopulation of T-ag to achieve a plasma membrane localization, as well as its chemical modifications by glycosylation (27, 70, 72) and palmitylation (38) . Monensin is a carboxylic ionophore that has been used extensively to investigate the functions of the Golgi apparatus (78) . It inhibits 0-glycosylation and terminal N-glycosylation events, and it interrupts the transport of certain glycoproteins that are routed through the Golgi apparatus in transit to the plasma membrane (1, 30, 31) . We used monensin to assess the functional role of the Golgi apparatus in the biosynthesis and transport of SV40 T-ag.
Initially, we examined the effect of monensin on overall protein synthesis in TC-7 cells. Despite numerous reports that monensin has no adverse effect on cellular protein In vitro translation of RNA isolated from free or membrane-bound polyribosomes of SV40-infected TC-7 cells. Free and membrane-bound polyribosome fractions were prepared from SV40-infected TC-7 cells as described in Materials and Methods. The RNA was isolated from each fraction by phenol-chloroform extraction and ethanol precipitation and was then resolubilized and quantitated. RNA (10 ,ug) from each fraction was translated in vitro, and the samples were immunoprecipitated with HAF. An immunoprecipitate prepared from in vitro translation of 10 ,ug of the total cytoplasmic RNA from infected TC-7 cells served as a control (lane 1). Lane 2, RNA from membrane-bound polyribosomes. Lane 3, RNA from free polyribosomes. This photograph is of an autoradiogram exposed for 4 weeks. Molecular weight markers are given in thousands. synthesis in a variety of different cell types, we found that typical monensin treatments inhibited overall protein synthesis in TC-7 cells (Fig. 6) . This was not a synergistic effect between the virus infection and the inhibitor treatment, because similar results were obtained with SV40-infected (top panel) and uninfected (bottom panel) cells. The results of monensin experiments, therefore, had to be interpreted cautiously, because any potentially specific effect had to be distinguished from a nonspecific effect due to the general inhibition of T-ag biosynthesis.
The effects of monensin on the overall biosynthesis, (66, 79, 82) , poly-ADP ribosylation (20) , glycosylation (27, 70, 72) , acylation (38) (73) presented evidence which also suggested that the secretory pathway is not utilized for the biosynthesis and transport of T-ag. Using a recombinant DNA approach, these investigators engineered a chimeric protein, HA-T-ag, composed of the aminoterminal signal sequence from the HA of influenza virus and the carboxy-terminal 694 amino acids of T-ag. The HA signal sequence mediated the transfer of HA-T-ag across the membrane of the RER, and the chimeric protein underwent N-glycosylation, presumably at a consensus recognition site located at amino acids 153 to 155 of the T-ag sequence. However, HA-T-ag did not proceed along the secretory pathway to achieve a plasma membrane localization; instead, it appeared to be stuck in the RER. The two observations, i.e., that HA-T-ag underwent N-glycosylation whereas WT T-ag did not and that HA-T-ag did not reach the plasma membrane whereas WT T-ag did, suggested that the secretory pathway is not normally used for the biosynthesis and transport of WT T-ag.
In summary, the results of this study and the study of Sharma et al. (73) eliminate the secretory pathway as a potential mechanism for the biosynthesis and processing of SV40 T-ag. We now face the task of designing a model to account for the glycosylation, palmitylation, and cell surface transport of T-ag, without invoking the ordinary mechanisms that are known to exist within the confines of the secretory pathway. From our examination of free and membranebound polyribosome fractions for the presence of SV40 early mRNA, we can conclude that the first step in the T-ag biosynthetic pathway is its translation on free polyribosomes in the cytoplasm of the cell. This is consistent with the previous isolation of T-ag-encoding early mRNA from free polyribosomes prepared from SV40-transformed mouse cells (57) . The processing events that proceed during and after the biosynthesis of T-ag, however, remain open to speculation and further investigation.
Theoretically, a subpopulation of T-ag could be targeted for transport to the plasma membrane by a unique structural feature, but recent structural comparisons of nT-ag and pmT-ag failed to reveal any differences (28) . The sorting process might rely upon a subtle structural difference that we are presently unable to detect, or it might be completely nonspecific. The latter possibility is intellectually unsatisfying, because available evidence suggests that pmT-ag plays an important functional role in SV40-induced cellular transformation (35, 46, 65 ; reviewed in reference 6). Finally, it is possible that the pmT-ag subpopulation is derived directly from the predominant nT-ag population (28, 73) . However, this model would require a novel mechanism of protein transport between the nucleus and plasma membrane, and it cannot account for the presence of pmT-ag in cells infected with a nuclear-transport-defective mutant of SV40 (43) .
On the basis of current knowledge of protein acylation mechanisms (69) , it is difficult to explain how T-ag would undergo palmitylation outside of the secretory pathway. However, it has been suggested that palmitylation of pmT-ag might occur at the plasma membrane itself by exchange with membrane lipids (47) . This proposal is consistent with the present conclusion that the Golgi apparatus is probably not involved in the modification or transport of T-ag. Interestingly, it has recently been noted that most acylated proteins are not N-glycosylated, suggesting that acylated integral membrane proteins may follow different intracellular transport pathways than cell surface glycoproteins (56) .
It is equally difficult to envision how T-ag can undergo glycosylation in the absence of the mechanisms available within the secretory pathway. However, a new mechanism that involves the formation of an unusual 0-glycosidic bond between N-acetylglucosamine and serine or threonine has recently been described (24, 68, 81) . In contrast to the secretory pathway, where glycosylation occurs exclusively on the lumenal side of cellular membranes, this glycosylation event appears to occur on the cytoplasmic or nucleoplasmic side of membranes (10, 25; J. A. Hanover, C. K. Cohen, M. C. Willingham, and M. K. Park, submitted for publication). We are currently exploring the exciting possibility that this newly recognized mechanism can explain the enigmatic observation that T-ag can undergo glycosylation without entering the cellular secretory pathway.
